Developing the new titanium alloys with excellent biomechanical compatibility has been an important research direction of surgical implants materials. Present paper summarizes the international researches and developm...Developing the new titanium alloys with excellent biomechanical compatibility has been an important research direction of surgical implants materials. Present paper summarizes the international researches and developments of biomedical titanium alloys. Aiming at increasing the biomechanical compatibility, it also introduces the exploration and improvement of alloy designing, mechanical processing, microstructure and phase transformation, and finally outlines the directions for scientific research on the biomedical titanium alloys in the future.展开更多
In this study, microstructural adjustments and mechanical properties of a cold-rolled near β-type alloy Ti-25Nb-3Zr-3Mo-2Sn （wt%） sheet were investigated. Microstructures and phase transformation products strongly ...In this study, microstructural adjustments and mechanical properties of a cold-rolled near β-type alloy Ti-25Nb-3Zr-3Mo-2Sn （wt%） sheet were investigated. Microstructures and phase transformation products strongly depended on aging temperatures. Solution treatments within single β-phase field removed the stress-induced at martensites and produced a few new lath-shaped ones, but metastable β phase still dominated. This is exactly the reason why current alloy exhibits the lowest modulus （54 GPa） and best elongation to fracture （39 %）, but the worst yield strength of only 340 MPa, at solutiontreated state. A fairly large number of ellipsoidal ω phase nanoparticles precipitated throughout parent β phase during aging at 380℃. These ω nanoparticles possess remarkable strengthening effect, but deteriorate ductility seriously. A novel post-aging process was proposed to remove brittle ω phase. By contrast, aging at 450 ℃ resulted in sufficient precipitation of fine needle-like α phase. This brought about the best combination of high yield strength （770 MPa） and moderate elastic modulus （75 GPa） and good elongation （15 %） for biomedical implants.展开更多
文摘Developing the new titanium alloys with excellent biomechanical compatibility has been an important research direction of surgical implants materials. Present paper summarizes the international researches and developments of biomedical titanium alloys. Aiming at increasing the biomechanical compatibility, it also introduces the exploration and improvement of alloy designing, mechanical processing, microstructure and phase transformation, and finally outlines the directions for scientific research on the biomedical titanium alloys in the future.
基金financially supported by Industrial Science Technology Project of Shaanxi Province (No. 2015GY160)Western Metal Materials Innovation Fund (No. XBCL03-18)International Cooperation and Exchanges of State Commission of Science Technology of China (No. 2014DFA30880)
文摘In this study, microstructural adjustments and mechanical properties of a cold-rolled near β-type alloy Ti-25Nb-3Zr-3Mo-2Sn （wt%） sheet were investigated. Microstructures and phase transformation products strongly depended on aging temperatures. Solution treatments within single β-phase field removed the stress-induced at martensites and produced a few new lath-shaped ones, but metastable β phase still dominated. This is exactly the reason why current alloy exhibits the lowest modulus （54 GPa） and best elongation to fracture （39 %）, but the worst yield strength of only 340 MPa, at solutiontreated state. A fairly large number of ellipsoidal ω phase nanoparticles precipitated throughout parent β phase during aging at 380℃. These ω nanoparticles possess remarkable strengthening effect, but deteriorate ductility seriously. A novel post-aging process was proposed to remove brittle ω phase. By contrast, aging at 450 ℃ resulted in sufficient precipitation of fine needle-like α phase. This brought about the best combination of high yield strength （770 MPa） and moderate elastic modulus （75 GPa） and good elongation （15 %） for biomedical implants.
